Mutation position is an important determinant for predicting cancer neoantigens

Area of Science:

• Immunology
• Oncology
• Computational Biology

Background:

• Tumor-specific mutations create neoantigens that can trigger CD8 T cell responses against cancer.
• Current methods like next-generation sequencing predict neoantigens, but many lack immunogenicity.
• Peptide binding affinity to MHC-I is a primary but imperfect neoantigen prioritization criterion.

Purpose of the Study:

• To systematically assess the immunogenicity of mutated peptides in mouse tumor models.
• To understand the relationship between peptide binding affinity and neoantigen immunogenicity.
• To improve neoantigen prioritization for cancer immunotherapy.

Main Methods:

• Systematic assessment of single amino acid mutation immunogenicity in mouse tumor models.
• Evaluation of predicted absolute and relative peptide binding affinity for MHC-I.
• Development of an improved immunogenicity model incorporating mutation-specific affinity predictions.

Main Results:

• Two classes of immunogenic mutations were identified based on residue type (anchor vs. non-anchor).
• For non-anchor mutations, absolute binding affinity predicts immunogenicity.
• For anchor mutations, relative affinity (compared to wild-type) is a better predictor.
• The refined model significantly enhances neoantigen ranking accuracy.
• Findings are validated in human cancer datasets.

Conclusions:

• Mutation location (anchor vs. non-anchor residue) is critical for predicting neoantigen immunogenicity.
• Integrating mutation-specific affinity predictions improves neoantigen selection for cancer vaccines.
• This approach holds promise for developing personalized neoantigen-specific immunotherapies.